[go: up one dir, main page]

MX2016008979A - Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. - Google Patents

Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.

Info

Publication number
MX2016008979A
MX2016008979A MX2016008979A MX2016008979A MX2016008979A MX 2016008979 A MX2016008979 A MX 2016008979A MX 2016008979 A MX2016008979 A MX 2016008979A MX 2016008979 A MX2016008979 A MX 2016008979A MX 2016008979 A MX2016008979 A MX 2016008979A
Authority
MX
Mexico
Prior art keywords
insulin
pharmaceutical formulations
stabilized pharmaceutical
derivatives
analogues
Prior art date
Application number
MX2016008979A
Other languages
English (en)
Inventor
Kamm Walter
Berchtold Harald
Bley Oliver
Loos Petra
Bidlingmaier Bernd
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2016008979A publication Critical patent/MX2016008979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina. En particular, la solicitud se refiere a una formulación farmacéutica que comprende (a) al menos un análogo y/o derivado de insulina; y (b) Zn(lI); y (c) sorbitol; y (d) opcionalmente protamina.
MX2016008979A 2014-01-09 2015-01-08 Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. MX2016008979A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925493P 2014-01-09 2014-01-09
EP14305025 2014-01-09
PCT/EP2015/050220 WO2015104314A1 (en) 2014-01-09 2015-01-08 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives

Publications (1)

Publication Number Publication Date
MX2016008979A true MX2016008979A (es) 2016-10-04

Family

ID=49949602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008979A MX2016008979A (es) 2014-01-09 2015-01-08 Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.

Country Status (11)

Country Link
US (4) US9839692B2 (es)
EP (1) EP3091995B1 (es)
JP (1) JP6641280B2 (es)
KR (1) KR20160104724A (es)
CN (2) CN112957455A (es)
AU (1) AU2015205624A1 (es)
CA (1) CA2932877A1 (es)
MX (1) MX2016008979A (es)
RU (1) RU2016132342A (es)
SG (1) SG11201604710XA (es)
WO (1) WO2015104314A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
CN114939156A (zh) 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
MX2016008979A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US11406720B2 (en) 2017-06-22 2022-08-09 The Regents Of The University Of Michigan Fibroblast growth factor receptor 2-specific peptide reagents and methods
AU2019377117B2 (en) 2018-11-07 2025-05-29 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
WO2025064695A1 (en) * 2023-09-21 2025-03-27 Villya LLC Compositions and methods for improving the solubility of insulin, insulin analogs, and a1c or glucose regulatory compounds

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB835638A (en) 1956-12-01 1960-05-25 Novo Terapeutisk Labor As Insulin crystal suspensions having a protracted effect
GB840870A (en) 1957-08-03 1960-07-13 Novo Terapeutisk Labor As Improvements in or relating to insulin preparations
US3091573A (en) 1958-05-12 1963-05-28 Novo Terapeutisk Labor As Quick acting insulin preparation
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3984696A (en) 1974-12-11 1976-10-05 Medi-Ray, Inc. Radiation guard for X-ray table
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPS63107941A (ja) 1985-11-28 1988-05-12 Wakunaga Pharmaceut Co Ltd 制ガン剤
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
US5006718A (en) 1989-07-21 1991-04-09 Lenhart Mark J X-ray shield for X-ray examination table
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE69416409T2 (de) 1993-06-21 1999-09-16 Novo Nordisk A/S, Bagsvaerd Asp-b28-insulinkristalle
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IT1265271B1 (it) 1993-12-14 1996-10-31 Alcatel Italia Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
ES2256888T3 (es) 1996-06-05 2006-07-16 Roche Diagnostics Gmbh Analogos de exendina, proceso para su preparacion y medicamentos que los contienen.
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
AU719361B2 (en) * 1996-06-20 2000-05-04 Novo Nordisk A/S Insulin preparations containing carbohydrates
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
BR9709845B1 (pt) 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
EP0981611A1 (en) 1997-02-05 2000-03-01 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
DE69838791T3 (de) 1997-08-08 2011-06-22 Amylin Pharmaceuticals, Inc., Calif. Neue exendinagonist verbindungen
PL340255A1 (en) 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
AU756836B2 (en) 1997-11-14 2003-01-23 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US5981964A (en) 1997-12-22 1999-11-09 Bruce J. McAuley Adjustable X-ray shield and on-line dosimetry system using same
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU762626B2 (en) 1998-06-05 2003-07-03 Nutrinia Ltd Insulin supplemented infant formula
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6227819B1 (en) 1999-03-29 2001-05-08 Walbro Corporation Fuel pumping assembly
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
WO2000066629A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
NZ535205A (en) 1999-10-04 2006-01-27 Chiron Corp Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US20010012829A1 (en) 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1377608B1 (en) 2001-04-02 2009-09-16 Novo Nordisk A/S Insulin precursors and a process for their preparation
WO2003002021A2 (en) 2001-06-29 2003-01-09 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
AU2003203146A1 (en) 2002-02-07 2003-09-02 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
EP1506230B1 (en) * 2002-05-07 2011-01-19 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
US7544657B2 (en) 2002-10-02 2009-06-09 Zealand Pharma A/S Stabilized Exendin-4 compounds
WO2004080480A1 (en) 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
JP4800959B2 (ja) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2005112949A1 (en) 2004-05-20 2005-12-01 Diamedica Inc. Use of drug combinations for treating insulin resistance
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
EP1791554A2 (en) 2004-09-17 2007-06-06 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
CA2581798A1 (en) 2004-10-05 2006-04-13 Petter Lybeck A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
US7957939B2 (en) 2005-02-01 2011-06-07 Canberra Industries, Inc. Maximum entropy signal detection method
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
DE102005046113A1 (de) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
ES2654520T3 (es) 2005-10-11 2018-02-14 Huntington Medical Research Institutes Agentes de formación de imágenes y métodos de uso de los mismos
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US20090324701A1 (en) 2006-01-20 2009-12-31 Diamedica, Inc. Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
EP1986674A4 (en) 2006-02-13 2009-11-11 Nektar Therapeutics PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
JP2009532422A (ja) 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１ペプチドアゴニスト
RU2419452C2 (ru) 2006-04-13 2011-05-27 Ипсен Фарма С.А.С. ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ
JP5269767B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
CN1931360B (zh) 2006-09-22 2013-02-13 江苏万邦生化医药股份有限公司 双时相精蛋白锌胰岛素注射液(30%)及其制备方法
AU2007298919C1 (en) 2006-09-22 2014-02-06 Novo Nordisk A/S Protease resistant insulin analogues
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
EP2167169B2 (de) 2007-06-14 2016-03-09 Sanofi-Aventis Deutschland GmbH Zweikammerkarpule mit aufsatz
EP2155303A1 (de) 2007-06-14 2010-02-24 Sanofi-Aventis Deutschland GmbH Zweikammerkarpule
CN101366692A (zh) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
CN101842083B (zh) 2007-11-01 2012-11-14 默克雪兰诺有限公司 Lh液体制剂
ES2543393T3 (es) 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
CN101444618B (zh) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
JP2011506442A (ja) 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
WO2009087081A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil
WO2009087082A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2010022870A1 (en) 2008-08-30 2010-03-04 Sanofi-Aventis Deutschland Gmbh Cartridge and needle system therefor
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
CN101670096B (zh) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
KR101419583B1 (ko) 2008-10-15 2014-07-25 인타르시아 세라퓨틱스 인코포레이티드 고농축 약물 입자, 제형, 현탁액 및 이들의 용도
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
TWI474833B (zh) 2009-04-01 2015-03-01 Genentech Inc 胰島素阻抗性疾病之治療
CN106109397A (zh) 2009-06-04 2016-11-16 爱尔开-阿贝优公司 包含至少一种肾上腺素能化合物的稳定化组合物
PL2612677T3 (pl) 2009-06-26 2015-10-30 Novo Nordisk As Preparat zawierający insulinę, nikotynamid i argininę
EP2451471A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Langsamwirkende insulinzubereitungen
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP2012532177A (ja) 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 熱及び振動安定性インスリン製剤
SG178195A1 (en) * 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US8748570B2 (en) 2010-05-25 2014-06-10 Syngene Limited Insulin analogues
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US20130331320A1 (en) * 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2670427A1 (en) 2011-02-02 2013-12-11 Sanofi-Aventis Deutschland GmbH Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
KR20140043755A (ko) 2011-05-13 2014-04-10 사노피-아벤티스 도이칠란트 게엠베하 ２형 당뇨병의 치료를 위한 릭시세나티드 및 메트포르민
EA201400031A1 (ru) 2011-06-17 2014-07-30 Галозим, Инк. Стабильные составы на основе фермента, разрушающего хиалуронан
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
PT2763690E (pt) 2011-10-04 2016-03-23 Sanofi Aventis Deutschland Lixisenatido para utilização no tratamento de estenose e/ou obstrução no sistema ductal pancreático
US20130096059A1 (en) 2011-10-04 2013-04-18 Jens Stechl Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
IN2014CN02616A (es) 2011-10-28 2015-06-26 Sanofi Aventis Deutschland
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
CN114939156A (zh) 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
MX2016008979A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.

Also Published As

Publication number Publication date
AU2015205624A1 (en) 2016-07-14
EP3091995B1 (en) 2024-03-20
US20150216981A1 (en) 2015-08-06
US20180125981A1 (en) 2018-05-10
SG11201604710XA (en) 2016-07-28
RU2016132342A3 (es) 2018-09-18
EP3091995A1 (en) 2016-11-16
RU2016132342A (ru) 2018-02-14
US20200297852A1 (en) 2020-09-24
CN105960249B (zh) 2021-03-16
US20230181739A1 (en) 2023-06-15
KR20160104724A (ko) 2016-09-05
JP2017502052A (ja) 2017-01-19
CN112957455A (zh) 2021-06-15
CN105960249A (zh) 2016-09-21
WO2015104314A1 (en) 2015-07-16
US9839692B2 (en) 2017-12-12
US10610595B2 (en) 2020-04-07
CA2932877A1 (en) 2015-07-16
JP6641280B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
MX2016008979A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EA201691911A1 (ru) Быстродействующие композиции инсулина
EP3094343A4 (en) Rapid action insulin formulations and pharmaceutical delivery systems
MX2016008977A (es) Formulaciones farmaceuticas de insulina aspart estabilizadas.
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
MX2016005395A (es) Formulacion estable de insulina glulisina.
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
EP3295952A4 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
EP3285758A4 (en) Co-crystal composition and its pharmaceutical use
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
IL253600A0 (en) Insulin analogs and preparations containing them
EP3237377A4 (en) Vitamin d3 derivatives and pharmaceutical use thereof
PH12015502242A1 (en) Lutein composition suitable for infant food formulations
EP3153156A4 (en) Composition based on a stabilized solution of active ingredients
PH12017501979A1 (en) Pharmaceutical compound
SG10201913433SA (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3242668A4 (en) Pharmaceutical formulations of xanthine or xanthine derivatives
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
GB201401706D0 (en) Nanoparticle-insulin and insulin analogue compositions
HK40014614A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
HK40015118A (en) Rapid-acting insulin analogues of enhanced stability
HK40014126A (en) Single-dose, ready-to-use injectable formulations